Saya L. Jacob, MD

S. Jacob1 ∙ E.L. Mayer2 ∙ N. Kacik3 ∙ A.M. Storniolo4 ∙ C. Isaacs5 ∙ I. Mayer6 ∙ V. Stearns7 ∙ R. Nanda8 ∙ J. Nangia9 ∙ A.J. Chien3 ∙ M. Moasser3 ∙ M. Melisko3 ∙ C. Wabl3 ∙ A. Muzikansky10 ∙ J. Geradts11 ∙ D.A. Dillon12 ∙ B.H. Park13 ∙ I. Krop14 ∙ A.C. Wolff15 ∙ B. Kochupurakkal2 ∙ G.I. Shapiro2,† ∙ H.S. Rugo TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer , ESMO Open, 11(4): 2026

Jacob S, Fisch S, Face C, Blum K, Chengappa M, Chaudhry S, LeVee A, Baclig NV, Soliman A, Huppert LA, Quandt Z, Quintal L, Idossa D, Melisko M, Chien AJ, Kim MO, Mortimer J, McCann K, Blaes A, Rugo HS. Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer , NPJ Breast Cancer, 11: 2025,144

Huppert LA, Mahtani R, Fisch S, Dempsey N, Premji S, Raimonde A, Jacob S, Quintal L, Melisko M, Chien J, Sandoval A, Carcas L, Ahluwalia M, Harpalani N, Hoppenworth J, Blaes A, Blum K, Kim MO, Idossa D, Rao R, Giridhar KV, Rugo HS. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC) , NPJ Breast Cancer, 11: 2025,34

Jacob S, Christofferson A, Fisch S, Norwood P, Castillo P, Yu H, Hirst G, Soliman H, Nanda R, Mukhtar RA, Ewing C, Majure M, Melisko M, Rugo HS, Esserman L, Price E, Chien AJ. Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy , Breast Cancer Res Treat: 2024

Zhang Q, Cai Z, Gerratana L, Davis AA, D'Amico P, Chawla A, Jacob S, Zhang Y, Jiao J, Qin W, Reduzzi C, Flaum L, Shah A, Gradishar WJ. Early Evaluation of Risk Stratification and Clinical Outcomes for Patients with Advanced Breast Cancer through Combined Monitoring of Baseline Circulating Tumor Cells and DNA. , Clin Cancer Res: 2024

Quandt Z, Jacob S, Fadlullah MZH, Wu C, Wu C, Huppert L, Levine LS, Sison P, Tsai KK, Chow M, Kang JH, Hwang J, Lee JC, Oglesby A, Venegas J, Brintz BJ, Tan AC, Anderson MS, Rosenblum MD, Young A, Daud AI. Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response , BJC Rep, 2: 2024,46

Jacob S, Johnson M, Roque B, Quintal L, Rugo HS, Melisko M, and Chien AJ. “Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.” , Clin Breast Cancer , 23(7): 2023,721-728

Saya Jacob, Edward Maldando, Meera Ragavan, Vanessa Kennedy, Rahul Banerjee, Amy Lin, Ana Velazquez. Development of Implementation of a Fertility Preservation Order Set In Comprehensive Cancer Center: A Quality and Equity Initiative. , American Society of Clinical Oncology Quality Symposium, Boston, MA.: 2023

Gerratana L, Reduzzi C, D'Amico P, Mazzeo R, Jacob S, Qiang W, Cristofanilli M. Clinical Perspectives in the Use of Liquid Biopsy in Metastatic Breast Cancer. , Current Cancer Research : 2023,10.1007/978-3-031-22903-9_21.

Jacob S, Johnson M, Roque B, Quintal L, Rugo HS, Melisko M, Chien AJ. Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer. , Clin Breast Cancer: 2023